ALLO Allogene Therapeutics Inc.

54.04
+3.84  (+8%)
Previous Close 50.2
Open 49.1
Price To Book 11.16
Market Cap 6,772,913,990
Shares 125,331,495
Volume 1,147,354
Short Ratio
Av. Daily Volume 1,065,785
Stock charts supplied by TradingView

NewsSee all news

  1. American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma

    ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host DiseaseAbstract Based on Data Cutoff in January 2020 Represents Limited

  2. Allogene Therapeutics Reports First Quarter 2020 Financial Results

    Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual MeetingPhase 1 ALPHA2 Trial for

  3. Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

    Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T TherapyALPHA Study Utilizes ALLO-647 Administered as Part of its Differentiated Lymphodepletion

  4. Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR™ Technology at the American Society of Gene & Cell Therapy (ASGCT) Virtual 2020 Annual Meeting

    Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T CellsPreclinical Studies Provide Evidence That Cytokine Signaling Can Increase TurboCAR T Cell Activity

  5. Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020

    Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Recruitment halted due to COVID-19.
UCART19 (PALL)
Acute lymphoblastic leukemia (ALL)
Recruitment halted due to COVID-19.
UCART19 - CALM
Refractory B-cell Acute Lymphoblastic Leukaemia
Phase 1/2 data due 4Q 2020.
ALLO-715 - UNIVERSAL
Multiple myeloma
Phase 1 initial data due at ASCO May 29, 2020.
ALLO-501 - ALPHA (ASCO)
Non-Hodgkin lymphoma (NHL)
Phase 1 trial to commence 2H 2020.
ALLO-715 with nirogacestat
Multiple myeloma
Phase 1 trial to be initiated 2Q 2020.
ALLO-501A (ALPHA2)

Latest News

  1. American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma

    ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host DiseaseAbstract Based on Data Cutoff in January 2020 Represents Limited

  2. Allogene Therapeutics Reports First Quarter 2020 Financial Results

    Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual MeetingPhase 1 ALPHA2 Trial for

  3. Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

    Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T TherapyALPHA Study Utilizes ALLO-647 Administered as Part of its Differentiated Lymphodepletion

  4. Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR™ Technology at the American Society of Gene & Cell Therapy (ASGCT) Virtual 2020 Annual Meeting

    Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T CellsPreclinical Studies Provide Evidence That Cytokine Signaling Can Increase TurboCAR T Cell Activity

  5. Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020

    Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company

  6. Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

    SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies

  7. MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies

    GAITHERSBURG, Md. and SOUTH SAN FRANCISCO, Calif., March 24, 2020 /PRNewswire/ -- MaxCyte, Inc., a global cell-based therapies and life sciences company, and Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage

  8. Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

    Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma and Phase 1 ALLO-715 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma On-Track for Q2 2020 and Q4 2020,

  9. Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

    Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company

  10. Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule

    SOUTH SAN FRANCISCO, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for

  11. Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

    Increasing BCMA Surface Expression with Gamma Secretase Inhibitor Nirogacestat May Enable Deep and Durable Responses to ALLO-715, an Investigational Anti-BCMA Allogeneic CAR T Therapy SOUTH SAN FRANCISCO, Calif. and

  12. Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell

  13. Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

    SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for

  14. Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell

  15. Allogene Therapeutics Reports Third Quarter 2019 Financial Results

    Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM)Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) with Data Expected in

  16. Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

    Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus

  17. Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

    Collaboration Will Evaluate Charge-altering Releasable Transporter System for mRNA Delivery to T CellsResearch Will Be Led by Stanford Researchers Robert Waymouth, Ph.D., Paul Wender, Ph.D. and Ronald Levy, M.D. SOUTH

  18. Allogene Therapeutics Announces September 2019 Investor Conference Schedule

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies